Skip to main content
An official website of the United States government
Email

Atezolizumab (MPDL3280A, RO5541267, TECENTRIQ®)

Agent Description

Atezolizumab is an Fc-engineered, humanized, monoclonal antibody that binds to PD-L1 and blocks interactions with the PD-1 and B7.1 receptors. Atezolizumab is a non-glycosylated IgG1 kappa immunoglobulin that has a calculated molecular mass of 145 kDa.

Mechanism of Action

Atezolizumab is a monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors. This releases the PD-L1/PD-1 mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity.

Classification

PD-L1 inhibitor

Molecular Target

PD-L1

Monograph

Atezolizumab is approved in the U.S. with the trade name of TECENTRIQ® for the following indications:

  • Atezolizumab is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
    • have disease progression during or following platinum-containing chemotherapy
    • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy
  • Metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Atezolizumab.

In addition to the two FDA approved indications above, atezolizumab is also being developed both as a monotherapy and in combination with standard treatments in a number of tumor types:

  • Atezolizumab monotherapy: NSCLC, Urothelial Carcinoma (UC)
  • Atezolizumab + chemotherapy: hematologic malignancies, triple negative breast cancer, urothelial carcinoma, NSCLC, SCLC
  • Atezolizumab + radiotherapy: NSCLC, UC
  • Atezolizumab + bevacizumab: renal cell carcinoma (RCC), urothelial carcinoma, colorectal cancer (CRC)
  • Atezolizumab + cobimetinib: CRC, UC, melanoma (BRAF wild-type)
  • Atezolizumab + ipilimumab: solid tumors
  • Atezolizumab + interferon-alpha: solid tumors
  • Atezolizumab + cobimetinib & vemurafenib: melanoma (BRAF-mutant), thyroid
  • Atezolizumab + BCG: UC
  • Atezolizumab + obinutuzumab: lymphomas
  • Atezolizumab + erlotinib: NSCLC
  • Atezolizumab + alectinib: NSCLC

View the atezolizumab package insert (PDF).

Studies of Interest

Areas of Interest

  • tumor types not currently under study by the Pharmaceutical Company Collaborator
  • novel combinations with standard treatments not currently under study by the Pharmaceutical Company Collaborator
  • studies in relevant patient subpopulations
  • correlative studies focused on relationships between immune biology and clinical response
  • early stage studies, e.g., neoadjuvant setting, in tumors not currently under study

Areas NOT of Interest

  • head-to-head studies with other PD-1/PD-L1 drugs
  • studies of novel dosing and schedules of administration
  • small under-powered randomized studies

Information collaborator would like included in investigator proposals

N/A

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Atezolizumab (MPDL3280A, RO5541267, TECENTRIQ®) was originally published by the National Cancer Institute.”

Email